Experiment 1185666

Details

PropertyValue
Pharmacology
Administration routeORAL
OrganismEmpty organism
CitationMATSUI,Y: OSHIMA,S: KADO,M: NAKAYAMA,M: SHIMOKATA,K: SAKAI,S: ITO,F: CHIKATA,E: HARA,K: KANDA,T: SHIMA,K: TAKENAKA,S: HOKAMA,S: GENGA,K:. (1987). PHASE II STUDY OF ORAL VP-16-213 IN SMALL CELL LUNG CANCER.. 60(12)
Amount utilized
Compound isolated
DiseaseSTUDIES INVOLVING PHASE 2 TRIALS IN 56 PATIENTS WITH SMALL CELL LUNG CANCER. THE OVERALL RESPONSE WAS OBTAINED IN 17 PATIENTS. THE DOSE-LIMITING FACTOR WAS LEUKOPENIA AND THROMBOCYTOPENIA.
Dose amount200 MG
Number1
Qualitative resultACTIVE
AnimalHUMAN ADULT
Per unitDAY
Dose expressionDOSE